Who
J. Scott Garland
Director
Company insider
Files Form 4 as: Director, Enliven Therapeutics; Director, Olema Pharmaceuticals; Director, LB Pharmaceuticals; Director, Day One Biopharmaceuticals; Director, ALX Oncology Holdings; Director, Calithera Biosciences; President and CEO, Portola Pharmaceuticals; Director, Karyopharm Therapeutics.
In numbers
- Trades disclosed
- 97
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $607K
- Companies
- 10
- Companies where not an officer
- 7
- First trade
- 20 Oct 2011
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Sep – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $201K13,000 at $15.47 | filing |
| 1 Oct 2026filed 5 Oct 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $607K13,000 at $46.67 | filing |
| 1 Oct 2026filed 5 Oct 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,000 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | OLMA Olema Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,500 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | OLMA Olema Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,500 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —48,072 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —28,700 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —37,500 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —48,072 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —28,700 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —37,500 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —32,335 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —22,500 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —32,335 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —22,500 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —15,000 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,427 at $0.00 | filing |
News
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst SaysELVN · dailypolitical.com · 21 Oct 2026Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearELVN · prnewswire.com · 14 Oct 2026
0 headlines in the last 90 days name J. Scott Garland; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.